Phase 4 N=20 Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis
Actinic Cheilitis
Primary: Number of Participants With a Change in Clearance From Baseline — 1; 1; 9; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=1,013 A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
Hepatitis C, Chronic
Primary: Percentage of Participants With Partial Early Virological Response (pEVR) to Study Treatment — 15.7 Percentage of participants
Phase 4 N=111 Local Steroid Injection vs Placebo in Carpal Tunnel Syndrome
Carpal Tunnel Syndrome
Primary: Number of Patients Who Have Had Carpal Tunnel Release Surgery on the Study Hand — 31; 34; 36 Participants
Phase 4 N=50 Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
COPD · Chronic Bronchitis · Emphysema
Primary: The Primary Outcome Measure is the Rate of Exacerbations as Defined Using the Winnipeg Criteria. — 5.5; 4 exacerbations per 12 weeks
Phase 4 N=33 Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life
Hypertension
Primary: Multidimensional Assessment of Fatigue (MAF) Questionnaire: Global Fatigue Score After 4 Weeks of Treatment on Each Drug/Dose Combination. — 18.5; 18.0; 21.0; 20.3 units…
Phase 4 N=9 Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide
Breast Cancer · Breast Cancer Female
Primary: Rate of Achieving Targeted Area Under the Curve (AUC) — 5; 3 Participants
Phase 4 N=11 Pilot Study of Velcade® in IgA Nephropathy
Chronic Kidney Disease · IgA Nephropathy
Primary: Proteinuria — 2.52; 1.43 grams per 24 hrs
Phase 4 N=343 PAIN - Postoperative Analgesia INvestigation
Postoperative Pain
Primary: Postoperative Pain as Assessed by a Numeric Pain Scale (NPS) — 5.05; 5.02 units on a scale — p=0.934
Phase 4 N=183 Treatment Study of Vitamin D Deficiency in Adolescents
Vitamin D Deficiency
Primary: Change in 25(OH)D Serum Level After Treatment for Vitamin D Deficiency (Deficiency Defined as 25(OH)D <20 ng/dL) — 6.2; 24.9; 21 ng/mL
Phase 4 N=108 Brilinta Taiwan Post Approval Safety Study
Non ST-elevation Myocardial Infarction
Primary: Number of Participants With Fatal/Life-threatening Bleedings — 4 Participants
Phase 4 N=40 The PIO II Study: In-office Post-op Placement of a Steroid-eluting Sinus Implant
Chronic Sinusitis, Ethmoidal
Primary: Inflammation Score — 26.7; 26.8; 21.5; 17.6 units on a scale — p=0.4709
Phase 4 N=57 Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females
Atherogenic Dyslipidemia · Obesity Associated Disorder
Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001
Phase 4 N=103 Immune and Hormone Response to Influenza Vaccine
Healthy
Primary: Change in Levels of Progesterone After Influenza Vaccination — 0.62; 0.43; 0.73; 0.59 ng/ml
Phase 4 N=560 Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.
Macular Edema
Primary: Change From Baseline to Week 52 in NEI VFQ-25 Total Score — 6.106 score on a scale
Phase 4 N=47 Nicotine Replacement Therapy in the Intensive Care Unit
Delirium · Psychomotor Agitation · Substance Withdrawal Syndrome
Primary: 30-day Mortality — 9.5; 7.7 percentage of patients